EQRX EQRx, Inc. Stock Quote

EQRX [NASD]

Index	-	P/E	-	EPS (ttm)	-7.65	Insider Own	16.37%	Shs Outstand	473.06M	Perf Week	-12.94%
Market Cap	2.38B	Forward P/E	-	EPS next Y	-0.83	Insider Trans	0.00%	Shs Float	407.89M	Perf Month	1.63%
Income	-	PEG	-	EPS next Q	-0.21	Inst Own	60.50%	Short Float	4.52%	Perf Quarter	21.17%
Sales	-	P/S	-	EPS this Y	58.40%	Inst Trans	1.36%	Short Ratio	7.69	Perf Half Y	52.76%
Book/sh	3.12	P/B	1.60	EPS next Y	-43.10%	ROA	-	Target Price	6.80	Perf Year	-49.70%
Cash/sh	3.26	P/C	1.53	EPS next 5Y	-	ROE	-	52W Range	2.63 - 9.99	Perf YTD	-26.98%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-50.15%	Beta	-
Dividend %	-	Quick Ratio	28.70	Sales past 5Y	-	Gross Margin	-	52W Low	89.35%	ATR	0.46
Employees	242	Current Ratio	28.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.60	Volatility	11.08% 8.86%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	52.10%	Profit Margin	-	Rel Volume	0.49	Prev Close	4.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 11 BMO	Payout	-	Avg Volume	2.40M	Price	4.98
Recom	1.70	SMA20	-4.10%	SMA50	1.31%	SMA200	-11.70%	Volume	1,191,880	Change	3.32%

Jun-13-22

Initiated

Goldman

Buy

Apr-22-22

Initiated

Cowen

Outperform

Mar-18-22

Initiated

Jefferies

Buy

$5.60

Aug-11-22 07:00AM	EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress GlobeNewswire -21.20%
Aug-07-22 04:10AM	EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer GlobeNewswire
Jul-28-22 08:00AM	EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 GlobeNewswire
Jul-03-22 08:22AM	Companies Like EQRx (NASDAQ:EQRX) Are In A Position To Invest In Growth Simply Wall St.
Jun-14-22 07:00AM	EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer GlobeNewswire
May-31-22 08:00AM	EQRx to Participate at Upcoming Investor Conferences GlobeNewswire +7.34%
May-26-22 05:00PM	EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022 GlobeNewswire
May-13-22 07:00AM	EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress GlobeNewswire +24.17%
Apr-29-22 08:00AM	EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022 GlobeNewswire
Apr-27-22 10:30AM	EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting GlobeNewswire
Mar-24-22 11:39AM	What Type Of Shareholders Own The Most Number of EQRx, Inc. (NASDAQ:EQRX) Shares? Simply Wall St. +6.15%
Mar-23-22 07:00AM	EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress GlobeNewswire
Mar-09-22 08:00AM	EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022 GlobeNewswire +5.42%
Mar-02-22 08:00AM	EQRx to Participate in Cowens 42nd Annual Health Care Conference GlobeNewswire
Jan-18-22 07:00PM	Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer GlobeNewswire
08:00AM	EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer GlobeNewswire
Jan-10-22 07:30AM	EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines GlobeNewswire
Jan-07-22 08:00AM	EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs GlobeNewswire
Jan-03-22 08:00AM	EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-21 06:35AM	We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth Simply Wall St.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience